Compared side by side

Cagrilintide vs eloralintide: how they differ

Reviewed How we check the libraryPublished by PepVault

The short answer

Both are weekly amylin drugs, built differently: cagrilintide acts on amylin receptors and on the calcitonin receptor, while eloralintide, from Eli Lilly, acts far more on amylin receptors than on the calcitonin receptor, and its half-life of about 14 days keeps levels nearly flat across the week. Neither is approved: cagrilintide is the amylin half of Novo Nordisk’s CagriSema, and eloralintide has been in phase 3 since late 2025. On their own, cagrilintide’s higher doses led to about 10–12% weight loss in trials, and eloralintide’s ran from about 9.5% on 1 mg to about 20% on 9 mg at 48 weeks in phase 2.

Side by side

ComparedCagrilintideEloralintide
CategoryMetabolic & GLP-1Metabolic & GLP-1
Also known asCagri, AM833, NNC0174-0833LY3841136, Elora
What it isA long-acting version of amylin, the fullness hormone the pancreas releases alongside insulin, given as a weekly shot.A once-weekly amylin drug from Eli Lilly, built to copy the fullness hormone the pancreas releases with insulin, and to act on its receptor more selectively than cagrilintide does.
How it worksLong-acting, lipidated analogue of amylin, the satiety hormone the pancreas releases with insulin. It activates amylin receptors and the calcitonin receptor (a non-selective amylin agonist); amylin promotes fullness, slows stomach emptying and holds back glucagon after meals. A fatty-acid chain stretches its half-life to about a week, so it is a weekly shot, usually run beside a GLP-1. Not approved on its own: it is the amylin half of Novo Nordisk's CagriSema.Once-weekly, long-acting agonist of the amylin receptor, the receptor for amylin, the fullness hormone the pancreas releases with insulin. Unlike cagrilintide, it is selective: it acts far more on amylin receptors than on the calcitonin receptor, a difference Lilly thinks may make it easier on the stomach. The idea is fewer calories through earlier fullness after meals rather than through the GLP-1 pathway. Its half-life of about 14 days keeps blood levels nearly flat across the week. Investigational, from Eli Lilly, in phase 3 since late 2025.
Commonly reportedFeeling full sooner and portions shrinking, with nausea or constipation after step-ups and some injection-site reactions. It is not approved on its own.In trials, fewer cravings, especially for sugar, and less food noise, with nausea and tiredness more likely on the higher doses. It is in phase 3 and not approved anywhere.
Studied rangeResearch range: 0.25–2.4 mg, starting dose 0.25 mg. Studied in research — not a recommendation.Research range: 1–9 mg, starting dose 3 mg. Studied in research — not a recommendation.
How oftenWeeklyWeekly
Half-life~1 week (measured in people: 159–195 hours in a phase 1b trial)~14 days (measured in people: phase 1 trials, Bhattachar 2026)
RouteSubQ injectionSubQ injection
Typical runTrials run it continuously: 26 weeks in phase 2, 68 weeks in phase 3. Community use is mostly as a weekly add-on to a GLP-1.Used continuously, once weekly, in its trials: 12 weeks in phase 1 and 48 weeks in phase 2; phase 3 runs about 75 weeks. No trial has tested stopping it.
EvidenceEstablished: clinical trials or FDA-approved use existsModerate: animal studies + some human data
Common side effectsNausea, constipation, diarrhea, injection-site reactionsNausea, fatigue, constipation, diarrhea, vomiting, decreased appetite, hair thinning, injection site reaction

Typical run: Community practice — opinions vary. Not a clinical recommendation.

A smiling man in a grey t-shirt in his living room, holding his phone

Model. Individual results vary.

PepVault for iPhone

Taking cagrilintide or eloralintide? Log it in PepVault

Each dose, each vial and your step-ups in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Week by week

Each entry’s cards by day window, as the compound pages show them. Day 1 is the day you start it.

Cagrilintide

  • Day 1–28 · 0.25 mg The 0.25 mg start
  • Day 29–364 · 0.5 mg 0.5 mg, the second step
  • Day 57–364 · 1 mg 1 mg, the middle step
  • Day 85–364 · 1.7 mg 1.7 mg, the step before 2.4 mg
  • Day 113+ · 2.4 mg 2.4 mg, the phase 3 dose

Every card for cagrilintide, with its sources

Eloralintide

  • Day 1–28 · 3 mg Fullness first, gently
  • Day 29–56 · 6 mg The step where nausea shows up
  • Day 57–336 · 6 mg Holding at 6 mg
  • Day 57–336 · 9 mg The top dose tested
  • Day 85–336 Fewer cravings, quieter food noise
  • Day 337+ A long-term medicine, not a course

Every card for eloralintide, with its sources

Questions people ask

How long do cagrilintide and eloralintide last?

The half-life of cagrilintide is ~1 week (measured in people: 159–195 hours in a phase 1b trial). The half-life of eloralintide is ~14 days (measured in people: phase 1 trials, Bhattachar 2026).

How often are cagrilintide and eloralintide taken?

Cagrilintide: weekly. Route: SubQ injection. Eloralintide: weekly. Route: SubQ injection.

How are cagrilintide and eloralintide dosed in research?

The research range for cagrilintide is 0.25–2.4 mg, with a 0.25 mg starting dose. The research range for eloralintide is 1–9 mg, with a 3 mg starting dose. Studied in research — not a recommendation.

What are the common side effects of cagrilintide and eloralintide?

For cagrilintide, the library lists: nausea, constipation, diarrhea, injection-site reactions. For eloralintide: nausea, fatigue, constipation, diarrhea, vomiting, decreased appetite, hair thinning, injection site reaction.

Each one in full

Track it in the app

PepVault for iPhone

Taking cagrilintide or eloralintide? Log it in PepVault

Each dose, each vial and your step-ups in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo